65. 原発性免疫不全症候群
[臨床試験数:413,薬物数:581(DrugBank:97),標的遺伝子数:68,標的パスウェイ数:202

Searched query = "Primary immunodeficiency", "X-SCID", "Reticular dysgenesis", "Adenosine deaminase deficiency", "Omenn syndrome", "Purine nucleoside phosphorylase deficiency", "CD8 deficiency", "ZAP-70 deficiency", "MHC class I deficiency", "MHC class II deficiency", "Combined immunodeficiency", "Wiskott-Aldrich syndrome", "Telangiectasia ataxia", "Nijmegen breakage syndrome", "Bloom syndrome", "Immunodeficiency, centromere region instability, facial anomalies syndrome", "ICF syndrome", "PMS2 deficiency", "Radiosensitivity, immunodeficiency, dysmorphic features, and learning difficulties syndrome", "RIDDLE syndrome", "Schimke syndrome", "Netherton syndrome", "Thymic hypoplasia", "DiGeorge syndrome", "22q11.2 deletion syndrome", "Hyper-IgE syndrome", "Hepatic venoocclusive immunodeficiency", "Immunodeficiency with central hepatic vein atresia", "Dyskeratosis congenita", "X-linked agammaglobulinaemia", "Common variable immunodeficiency", "Hyper-IgM syndrome", "Isolated IgG subclass deficiency", "Selective IgA deficiency", "Specific antibody production deficiency", "Infant transient hypogammaglobulinemia", "Chédiak-Higashi syndrome", "Chediak-Higashi syndrome", "X-linked lymphoproliferative syndrome", "SAP deficiency", "SH2D1A/SLAM-associated protein deficiency", "XIAP deficiency", "X-linked inhibitor of apoptosis deficiency", "Autoimmune lymphoproliferative syndrome", "ALPS", "Familial hemophagocytic syndrome", "Perforin deficiency", "Munc13-4 deficiency", "Syntaxin 11 deficiency", "Munc18-2 deficiency", "Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy", "APECED", "Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome", "IPEX syndrome", "CD25 deficiency", "ITCH deficiency", "Primary phagocytic dysfunction", "Severe congenital neutropenia", "Cyclic neutropenia", "Hermanskyi-Pudlak syndrome type 2", "Hermanskyi-Pudlak syndrome 2", "Griscelli syndrome type 2", "Griscelli syndrome 2", "p14 deficiency", "Warts, hypogammaglobulinemia, infections, myelokathexis syndrome", "WHIM syndrome", "Glycogen storage disease type Ib", "Leukocyte adhesion deficiency", "Shwachman-Diamond syndrome", "Chronic granulomatous disease", "Myeloperoxidase deficiency", "Mendelian susceptibility to mycobacterial disease", "MSMD", "Anhidrotic ectodermal dysplasia with immunodeficiency", "EDA-ID", "Interleukin-1 receptor-associated kinase-4 deficiency", "IRAK4 deficiency", "IMyD88 deficiency", "Chronic mucocutaneous candidiasis", "Epidermodysplasia verruciformis", "Herpes simplex encephalitis", "Caspase recruitment domain family member 9 deficiency", "CARD9 deficiency", "Trypanosomiasis", "Congenital complement deficiency", "C1q deficiency", "CC1r deficiency", "CC1s deficiency", "CC2 deficiency", "CC3 deficiency", "CC4 deficiency", "CC5 deficiency", "CC6 deficiency", "CC7 deficiency", "CC8 deficiency", "CC9 deficiency", "Factor D deficiency", "Properdin deficiency", "Factor I deficiency", "Factor H deficiency", "MASP1 deficiency", "3MC syndrome", "Mannose-binding protein-associated serine protease 2 deficiency", "MASP2 deficiency", "FCN3", "Hereditary angioedema type 1", "Hereditary angioedema type I", "C1 inhibitor deficiency type 1", "C1 inhibitor deficiency type I", "Hereditary angioedema type 2", "Hereditary angioedema type II", "C1 inhibitor deficiency type 2", "C1 inhibitor deficiency type II", "Hereditary angioedema type 3", "Hereditary angioedema type III", "C1 inhibitor deficiency type 3", "C1 inhibitor deficiency type III"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
10 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-000338-36-NO
(EUCTR)
06/11/202004/02/2020Not ApplicableOpen-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study - OLE-IEDAT Patient with neurological symptoms of Ataxia Telangiectasia
MedDRA version: 21.0;Level: PT;Classification code 10003594;Term: Ataxia telangiectasia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Dexamethasone sodium phosphate
INN or Proposed INN: Dexamethasone sodium phosphate
Other descriptive name: DEXAMETHASONE SODIUM PHOSPHATE PH. EUR.
EryDel S.p.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
155Phase 3United States;Spain;Poland;Belgium;Australia;Tunisia;Germany;Norway;United Kingdom;Italy;India
2EUCTR2018-000338-36-GB
(EUCTR)
27/05/202020/01/2020Not ApplicableOpen-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study - OLE-IEDAT, version 5.0 Patient with neurological symptoms of Ataxia Telangiectasia
MedDRA version: 21.0;Level: PT;Classification code 10003594;Term: Ataxia telangiectasia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Dexamethasone sodium phosphate
INN or Proposed INN: Dexamethasone sodium phosphate
Other descriptive name: DEXAMETHASONE SODIUM PHOSPHATE PH. EUR.
EryDel S.p.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
51Phase 3United States;Spain;Poland;Belgium;Australia;Israel;Norway;Germany;United Kingdom;India
3EUCTR2018-000338-36-DE
(EUCTR)
20/09/201821/06/2018Not ApplicableOpen-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study - OLE-IEDAT Patient with neurological symptoms of Ataxia Telangiectasia
MedDRA version: 21.0;Level: PT;Classification code 10003594;Term: Ataxia telangiectasia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Dexamethasone sodium phosphate
INN or Proposed INN: Dexamethasone sodium phosphate
Other descriptive name: DEXAMETHASONE SODIUM PHOSPHATE PH. EUR.
EryDel S.p.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
155Phase 3United States;Spain;Poland;Belgium;Australia;Israel;Norway;Germany;United Kingdom;India
4EUCTR2018-000338-36-ES
(EUCTR)
31/05/201805/04/2018Not ApplicableOpen-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study - OLE-IEDAT Patient with neurological symptoms of Ataxia Telangiectasia
MedDRA version: 20.1;Level: PT;Classification code 10003594;Term: Ataxia telangiectasia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Dexamethasone sodium phosphate
INN or Proposed INN: Dexamethasone sodium phosphate
Other descriptive name: DEXAMETHASONE SODIUM PHOSPHATE PH. EUR.
EryDel S.p.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
61Phase 3United States;Poland;Belgium;Spain;Australia;Israel;Norway;Germany;Italy;United Kingdom;India
5EUCTR2015-005241-31-IT
(EUCTR)
02/11/201628/02/2018n/aA Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Patients with Ataxia Telangiectasia - EDS in Ataxia Telangiectasia Patients - IEDAT-02 Patient with neurological symptoms of Ataxia Telangiectasia
MedDRA version: 20.1;Level: PT;Classification code 10003594;Term: Ataxia telangiectasia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Dexametasone Fosfato Sodico
INN or Proposed INN: Dexametasone Fosfato Sodico
Other descriptive name: DEXAMETHASONE SODIUM PHOSPHATE PH. EUR.
ERYDEL S.P.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 3United States;Spain;Costa Rica;Turkey;Israel;Italy;United Kingdom;Belgium;Poland;Australia;Tunisia;Germany;Norway
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2015-005241-31-DE
(EUCTR)
14/09/201627/05/2016n/aA Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Patients with Ataxia Telangiectasia - Ataxia Telangiectasia - Treatment with EryDex SysTem - ATTEST Patient with neurological symptoms of Ataxia Telangiectasia
MedDRA version: 21.0;Level: PT;Classification code 10003594;Term: Ataxia telangiectasia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Dexamethasone sodium phosphate
INN or Proposed INN: Dexamethasone sodium phosphate
Other descriptive name: DEXAMETHASONE SODIUM PHOSPHATE PH. EUR.
EryDel S.p.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
175Phase 3United States;Spain;Poland;Belgium;Australia;Israel;Tunisia;Norway;Germany;United Kingdom;Italy;India
7EUCTR2015-005241-31-ES
(EUCTR)
31/05/201609/06/2016n/aA Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Patients with Ataxia Telangiectasia - EDS in Ataxia Telangiectasia Patients - IEDAT-02 Patient with neurological symptoms of Ataxia Telangiectasia
MedDRA version: 19.0;Level: PT;Classification code 10003594;Term: Ataxia telangiectasia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Dexamethasone sodium phosphate
INN or Proposed INN: Dexamethasone sodium phosphate
Other descriptive name: DEXAMETHASONE SODIUM PHOSPHATE PH. EUR.
EryDel S.p.A.NULLNot RecruitingFemale: yes
Male: yes
180Phase 3United States;Spain;Costa Rica;Turkey;Israel;United Kingdom;Italy;Belgium;Poland;Australia;Tunisia;Germany;Norway
8EUCTR2005-003201-81-DE
(EUCTR)
20/12/200619/01/2007GACHE: German trial of Acyclovir and Corticosteroids in Herpes-simplex-virus-Encephalitis. A multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial. - GACHEGACHE: German trial of Acyclovir and Corticosteroids in Herpes-simplex-virus-Encephalitis. A multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial. - GACHE Herpes simplex virus type-1 (HSV-1) is the most frequent cause of fatal sporadic encephalitis in humans. Herpes simplex encephalitis (HSE) was one of the first viral infections to be successfully treated with antiviral drugs. Mortality has been significantly reduced since the introduction of acyclovir, a specific inhibitor of HSV replication. Despite appropriate and promptly initiated antiviral therapy the incidence of persistent neurological deficits remain unacceptably high.Trade Name: Fortecortin Inject 40 mg Amp.
Product Name: Fortecortin
INN or Proposed INN: dexamethasone 21-dihydrogen phosphate
Universitätsklinikum HeidelbergNULLNot RecruitingFemale: yes
Male: yes
450Phase 3Germany
9EUCTR2018-000338-36-PL
(EUCTR)
06/11/2018Not ApplicableOpen-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study - OLE-IEDAT Patient with neurological symptoms of Ataxia Telangiectasia
MedDRA version: 21.0;Level: PT;Classification code 10003594;Term: Ataxia telangiectasia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Dexamethasone sodium phosphate
INN or Proposed INN: Dexamethasone sodium phosphate
Other descriptive name: DEXAMETHASONE SODIUM PHOSPHATE PH. EUR.
EryDel S.p.A.NULLNAFemale: yes
Male: yes
155Phase 3United States;Spain;Belgium;Poland;Australia;Tunisia;Norway;Germany;United Kingdom;Italy;India
10EUCTR2015-005241-31-PL
(EUCTR)
01/07/2016n/aA Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Patients with Ataxia Telangiectasia - EDS in Ataxia Telangiectasia Patients - IEDAT-02 Patient with neurological symptoms of Ataxia Telangiectasia
MedDRA version: 21.0;Level: PT;Classification code 10003594;Term: Ataxia telangiectasia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Dexamethasone sodium phosphate
INN or Proposed INN: Dexamethasone sodium phosphate
Other descriptive name: DEXAMETHASONE SODIUM PHOSPHATE PH. EUR.
EryDel S.p.A.NULLNAFemale: yes
Male: yes
180Phase 3United States;Spain;Costa Rica;Turkey;Israel;United Kingdom;Italy;India;Poland;Belgium;Australia;Norway;Tunisia;Germany